Anavex Life Sciences Corp (AVXL)

[falconer66a]

Stock Advisor Recommendations Now At Play

As always, a very informative posting, RedShoulder.

These are just the first investor advisory postings more accurately telling both the sound science of the Anavex drug, and how it will treat large numbers of people. There will be more and more of them.

I, too, use the Charles Schwab brokerage, and was delighted to see this headline on my Schwab screen this morning: --BTIG Starts Anavex Life Sciences at Buy with $35 Price Target.

I notice also that Schwab now posts a B investment grade on Anavex, meaning "Outperform." Formerly, none was posted (the Schwab grade scale: A, B, C, D, F).

The word (of the Anavex science) is finally getting out, being understood and applied to understandings of how it will work for the AVXL share price.

As I've contended before, the first giant, irrevocable thing that will propel the Anavex share price will the article in the New York Times, "New Drug Shows Promise for CNS Diseases." That should be right after the FDA approves blarcamesine for Rett syndrome; based upon all of the existing safety and efficacy data, that will surely happen.

For AVXL shareholders (and CNS disease patients), 2022 is going to be quite a year.